Planning Strategies Inc.’s 4D Molecular Therapeutics FDMT Stock Holding History

Planning Strategies Inc.’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.68K	Buy	+502	New	+$4.89K	﹤0.01%	385

Other funds holding FDMT

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Planning Strategies Inc.'s FDMT Position: Q2 2026 in Review

Planning Strategies Inc. opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 502 shares worth $6.68K. The stake represents ﹤0.01% of the portfolio and ranks #385 among its holdings.

22 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Planning Strategies Inc. held 502 shares of 4D Molecular Therapeutics worth $6.68K as of Q2 2026.
4D Molecular Therapeutics was a new Planning Strategies Inc. position in Q2 2026.
4D Molecular Therapeutics made up ﹤0.01% of Planning Strategies Inc.'s portfolio in Q2 2026, its #385 holding.
22 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Planning Strategies Inc.'s 13F filing for Q2 2026, filed 27 Jul 2026.